• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于伴有临床明显淋巴结转移(cN1)、术后甲状腺球蛋白水平低的甲状腺乳头状癌患者,能否免除放射性碘治疗?

Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine?

机构信息

Santa Casa de Belo Horizonte, Minas Gerais, Brazil.

出版信息

Endocrine. 2020 Dec;70(3):552-557. doi: 10.1007/s12020-020-02414-1. Epub 2020 Jul 11.

DOI:10.1007/s12020-020-02414-1
PMID:32653994
Abstract

BACKGROUND

The study evaluated the recurrence rate in patients with papillary thyroid carcinoma (PTC) and clinically apparent lymph node metastases (LNM) (cN1) who had low thyroglobulin (Tg) after total thyroidectomy and who were not submitted to adjuvant therapy with I.

METHODS

This was a prospective study. It included 82 cN1 patients (≤3 LNM ≤1.5 cm without macroscopic extracapsular extension) with tumors ≤4 cm without macroscopic extrathyroid invasion (T1-2) and who after thyroidectomy had unstimulated Tg (u-Tg) < 0.3 ng/ml, negative antithyroglobulin antibodies (TgAb), and neck ultrasonography (US) showing no anomalies. The patients were not submitted to therapy with I.

RESULTS

The time of follow-up ranged from 24 to 156 months (median 84 months). Seventy-nine patients (96.3%) continued to have u-Tg < 0.3 ng/ml and negative US. Three patients (3.6%) exhibited an increase in Tg and structural recurrence was detected in two. After treatment, these patients achieved u-Tg < 1 ng/ml and the imaging methods revealed no apparent tumor.

CONCLUSIONS

The results suggest that even cN1 patients, given the absence of extensive LNM or other adverse findings, who have low Tg and neck US showing no anomalies after thyroidectomy do not require radioiodine.

摘要

背景

本研究评估了甲状腺乳头状癌(PTC)伴临床明显淋巴结转移(cN1)且全甲状腺切除术后甲状腺球蛋白(Tg)水平低[未刺激Tg(u-Tg)<0.3ng/ml]且未接受放射性碘(I)辅助治疗的患者的复发率。

方法

这是一项前瞻性研究,共纳入 82 例 cN1 患者(≤3 枚淋巴结转移且最大直径≤1.5cm 且无肉眼外侵犯),肿瘤最大直径≤4cm 且无肉眼甲状腺外侵犯(T1-2),且术后 u-Tg<0.3ng/ml,抗甲状腺球蛋白抗体(TgAb)阴性,颈部超声(US)无异常。这些患者未接受 I 治疗。

结果

随访时间为 24-156 个月(中位数 84 个月)。79 例(96.3%)患者持续 u-Tg<0.3ng/ml 且颈部 US 无异常。3 例(3.6%)患者 Tg 升高,其中 2 例发现结构性复发。经过治疗,这些患者的 u-Tg<1ng/ml,影像学方法未发现明显肿瘤。

结论

即使 cN1 患者淋巴结转移不广泛或无其他不良发现,且全甲状腺切除术后 Tg 水平低、颈部 US 无异常,也不一定需要接受放射性碘治疗。

相似文献

1
Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine?对于伴有临床明显淋巴结转移(cN1)、术后甲状腺球蛋白水平低的甲状腺乳头状癌患者,能否免除放射性碘治疗?
Endocrine. 2020 Dec;70(3):552-557. doi: 10.1007/s12020-020-02414-1. Epub 2020 Jul 11.
2
Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.术后低水平非刺激甲状腺球蛋白作为避免放射性碘消融的标准。
Endocr Relat Cancer. 2016 Jan;23(1):47-52. doi: 10.1530/ERC-15-0458. Epub 2015 Oct 26.
3
Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk 'with higher risk features'.术后低水平非刺激甲状腺球蛋白作为具有较高风险特征的中度风险甲状腺乳头状癌患者低放射性碘活性指征的标准。
Clin Endocrinol (Oxf). 2016 Sep;85(3):453-8. doi: 10.1111/cen.13024. Epub 2016 Feb 12.
4
Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.对复发风险处于中等水平的甲状腺乳头状癌患者采用1.1吉贝可(30毫居里)碘-131进行甲状腺消融。
Thyroid. 2014 May;24(5):826-31. doi: 10.1089/thy.2013.0479. Epub 2014 Jan 24.
5
Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.将术后刺激甲状腺球蛋白水平控制在 1ng/ml 以下作为一种标准,以避免放射性碘消融治疗低危型甲状腺乳头状癌患者。
Thyroid. 2012 Nov;22(11):1140-3. doi: 10.1089/thy.2012.0190. Epub 2012 Oct 10.
6
Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.未接受放射性碘治疗的伴有微小甲状腺外侵犯的甲状腺乳头状癌患者的复发风险。
J Endocrinol Invest. 2019 Jun;42(6):687-692. doi: 10.1007/s40618-018-0969-y. Epub 2018 Oct 23.
7
Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine.甲状腺乳头癌患者的自然病史、明显疾病(结构性或生化性)的预测因素和对初始放射性碘治疗无反应但自发良好反应。
Endocrine. 2022 Jun;76(3):671-676. doi: 10.1007/s12020-022-03040-9. Epub 2022 Mar 28.
8
Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis.乳头状甲状腺癌患者存在持续性和复发性疾病,伴有临床明显(cN1)但不广泛的淋巴结受累,且无其他预后不良因素。
Arch Endocrinol Metab. 2015 Aug;59(4):285-91. doi: 10.1590/2359-3997000000081.
9
Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin.低放射性碘消融治疗甲状腺乳头状癌患者的长期结果及术后非刺激状态下甲状腺球蛋白的预测价值
Nucl Med Commun. 2016 Oct;37(10):1024-9. doi: 10.1097/MNM.0000000000000562.
10
Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies.全甲状腺切除术后无明显疾病但抗甲状腺球蛋白抗体升高的甲状腺乳头状癌患者放射性碘的适应证。
Clin Endocrinol (Oxf). 2022 Jan;96(1):82-88. doi: 10.1111/cen.14570. Epub 2021 Aug 4.

引用本文的文献

1
How Many Lymph Nodes are Enough in Thyroidectomy? A Cohort Study Based on Real-World Data.甲状腺切除术中多少个淋巴结才算足够?一项基于真实世界数据的队列研究。
Ann Surg Oncol. 2025 Feb;32(2):1149-1157. doi: 10.1245/s10434-024-16391-6. Epub 2024 Nov 9.
2
Long-term efficacy of lobectomy for stage T1 papillary thyroid carcinoma with varying degrees of lymph node metastasis.不同程度淋巴结转移的 T1 期甲状腺乳头状癌行 lobectomy 的长期疗效。
Front Endocrinol (Lausanne). 2024 Aug 8;15:1453601. doi: 10.3389/fendo.2024.1453601. eCollection 2024.

本文引用的文献

1
In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation.在经过恰当选择的分化型甲状腺癌患者中,甲状腺球蛋白抗体在甲状腺切除术后会下降,仅其存在不应作为放射性碘消融的指征。
Arch Endocrinol Metab. 2019 May-Jun;63(3):293-299. doi: 10.20945/2359-3997000000123. Epub 2019 Apr 25.
2
Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation.术后甲状腺球蛋白及颈部超声在风险再分层及决定进行¹³¹I消融中的应用
J Clin Endocrinol Metab. 2017 Mar 1;102(3):893-902. doi: 10.1210/jc.2016-2860.
3
Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
应用术后刺激甲状腺球蛋白筛选低危型甲状腺乳头状癌患者行放射性碘清甲治疗。
Head Neck. 2010 Jun;32(6):689-98. doi: 10.1002/hed.21371.